869631-11-8

Basic information

• Product Name: O-Desethyl Candesartan Cilexetil
• Synonyms: O-Desethyl Candesartan Cilexetil ;2,3-Dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-1H-benziMidazole-4-carboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester;Candesartan Cilexetil EP IMpurity B;1-(Cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl) methyl)-2-hydroxy-1H-benzo[d]imidazole-7-carboxylate;Candesartan Impurity 1
• CAS NO: 869631-11-8
• Molecular Formula: C₃₁H₃₀N₆O₆
• Molecular Weight: 581.59856
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 869631-11-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 237-239?C (dec.)
• Appearance: /
• Density: 1.437g/cm³
• Refractive Index: 1.677
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.16±0.10(Predicted)
• CAS DataBase Reference: O-Desethyl Candesartan Cilexetil(CAS DataBase Reference)
• NIST Chemistry Reference: O-Desethyl Candesartan Cilexetil(869631-11-8)
• EPA Substance Registry System: O-Desethyl Candesartan Cilexetil(869631-11-8)

Safety Data

• Hazardous Substances Data: 869631-11-8(Hazardous Substances Data)

Usage

Description

O-Desethyl Candesartan Cilexetil, also known as Candesartan Cilexetil EP Impurity B, is a chemical compound derived from Candesartan Cilexetil. It is used as an impurity in the preparation of Candesartan Cilexetil, an antihypertensive medication.

Uses

Used in Pharmaceutical Industry:
O-Desethyl Candesartan Cilexetil is used as an impurity in the preparation of Candesartan Cilexetil (CAT# C175580), an antihypertensive medication. It plays a crucial role in ensuring the quality and purity of the final product, which is essential for its therapeutic efficacy and safety.
Additionally, O-Desethyl Candesartan Cilexetil can be used for the preparation of Candesartan cilexetil, further emphasizing its importance in the pharmaceutical industry for the development and production of antihypertensive drugs.
It may also be obtained as a degradation product of Candesartan Cilexetil in liquid chromatography studies, providing valuable insights into the stability and degradation pathways of the drug, which can be useful for optimizing manufacturing processes and ensuring the quality of the final product.

InChI:InChI=1/C31H30N6O6/c1-19(42-31(40)43-22-8-3-2-4-9-22)41-29(38)25-12-7-13-26-27(25)37(30(39)32-26)18-20-14-16-21(17-15-20)23-10-5-6-11-24(23)28-33-35-36-34-28/h5-7,10-17,19,22H,2-4,8-9,18H2,1H3,(H,32,39)(H,33,34,35,36)

Upstream product

• 145040-37-5 candesartan cilexetil 
• 170791-09-0 cilexetil trityl candesartan 

Relevant articles and documents

Identification, synthesis and structural determination of some impurities of candesartan cilexetil

All principal candesartan cilexetil impurities and/or degradation products were synthesized and identified. The differentiation of N-l and N-2 ethylated candesartan cilexetil derivatives was performed using ID and 2D NMR experiments. The influence of the magnetic field on the resolution and sensitivity of NMR experiments is shown. Selective hydrolysis of these compounds then provided corresponding producrs of hydrolysis of the ethoxy group. Institute of Organic Chemistry and Biochemistry.

STABLE MICRONIZED CANDESARTAN CILEXETIL AND METHODS FOR PREPARING THEREOF

The invention encompasses sable candesartan cilexetil of fine particle size, wherein desethyl-candesartan (desethyl-CNS) within the stable candesartan cilexetil does not increase to more than about 0.1%w/w by HPLC relative to the initial amount of candesartan cilexetil, when the stable candesartan cilexetil is maintained at a temperature of about 550°C for at least 2 weeks, methods of making the same and pharmaceutical compositions thereof.